4.7 Article

MicroRNA-138 Increases Chemo-Sensitivity of Glioblastoma through Downregulation of Survivin

Journal

BIOMEDICINES
Volume 9, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines9070780

Keywords

glioblastoma (GBM); microRNA-138 (miR-138); BIRC5; survivin; temozolomide (TMZ)

Funding

  1. Cancer Prevention and Research Institute of Texas (CPRIT) [RP200615]
  2. National Institutes of Health National Cancer Institute (NCI) [R03 CA252770]
  3. University of Texas Health Science Center at Houston Neurosciences (UTHN)
  4. American Cancer Society (ACS) [RSG-19-185-01-MPC]
  5. NCI [R01 CA150153, P01 CA163205]
  6. National Institutes of Health [R01 LM012806]
  7. CPRIT [RP180734, RP210045]

Ask authors/readers for more resources

The study demonstrated that overexpression of miR-138 sensitizes GBM cells to TMZ treatment and increases apoptotic cell death. Mechanistically, miR-138 directly repressed Survivin expression to enhance apoptosis induced by TMZ.
Glioblastoma (GBM) is one of the most deadly cancers and poorly responses to chemotherapies, such as temozolomide (TMZ). Dysregulation of intrinsic signaling pathways in cancer cells are often resulted by dysregulated tumor suppressive microRNAs (miRNAs). Previously, we found miR-138 as one of tumor suppressive miRNAs that were significantly down-regulated in GBM. In this study, we demonstrated that ectopic over-expression of miR-138 sensitizes GBM cells to the treatment of TMZ and increased apoptotic cell death. Mechanistically, miR-138 directly repressed the expression of Survivin, an anti-apoptotic protein, to enhance caspase-induced apoptosis upon TMZ treatment. Using an intracranial GBM xenograft mice model, we also showed that combination of miR-138 with TMZ increases survival rates of the mice compared to the control mice treated with TMZ alone. This study provides strong preclinical evidence of the therapeutic benefit from restoration of miR-138 to sensitize the GBM tumor to conventional chemotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available